Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. - Wikidata - awgldk - TriplyDB

Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse.

Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse.

http://www.wikidata.org/entity/Q33835737

about

Structure of the human κ-opioid receptor in complex with JDTic Role of kappa-opioid receptors in stress and anxiety-related behavior.Drug withdrawal conceptualized as a stressor.New mechanisms and perspectives in nicotine withdrawal Negative affective states and cognitive impairments in nicotine dependence Nicotine dependence produces hyperalgesia: role of corticotropin-releasing factor-1 receptors (CRF1Rs) in the central amygdala (CeA).Mouse models for studying genetic influences on factors determining smoking cessation success in humans.Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity The clinical implications of mouse models of enhanced anxiety.Analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in vitro and in vivo opioid receptor antagonist activity Role of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats.Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity Major Depressive Disorder and Kappa Opioid Receptor Antagonists.Learning and memory impairment induced by salvinorin A, the principal ingredient of Salvia divinorum, in wistar rats.Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats.The long-lasting effects of JDTic, a kappa opioid receptor antagonist, on the expression of ethanol-seeking behavior and the relapse drinking of female alcohol-preferring (P) rats The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety.Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.The opioid receptors as targets for drug abuse medication The role of the dynorphin/κ opioid receptor system in anxiety.Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner.Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake Roles of nucleus accumbens CREB and dynorphin in dysregulation of motivation.Relative Timing Between Kappa Opioid Receptor Activation and Cocaine Determines the Impact on Reward and Dopamine Release Development of κ opioid receptor antagonists.The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration.Animal models of nicotine exposure: relevance to second-hand smoking, electronic cigarette use, and compulsive smoking.Stress-induced activation of the dynorphin/κ-opioid receptor system in the amygdala potentiates nicotine conditioned place preference.Two short-acting kappa opioid receptor antagonists (zyklophin and LY2444296) exhibited different behavioral effects from the long-acting antagonist norbinaltorphimine in mouse anxiety tests Effects of the kappa opioid receptor antagonist, norbinaltorphimine, on stress and drug-induced reinstatement of nicotine-conditioned place preference in mice.4β-Methyl-5-(3-hydroxyphenyl)morphan opioid agonist and partial agonist derived from a 4β-methyl-5-(3-hydroxyphenyl)morphan pure antagonist Preclinical evidence of new opioid modulators for the treatment of addiction.The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.Psychiatric neural networks and neuropharmacology: Selected advances and novel implications The discovery and development of the N-substituted trans-3,4-dimethyl-4-(3'-hydroxyphenyl)piperidine class of pure opioid receptor antagonists.Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.Endogenous opioid system: a promising target for future smoking cessation medications.Neuropeptide systems and new treatments for nicotine addiction.Local anesthetic lidocaine delivery system: chitosan and hyaluronic acid-modified layer-by-layer lipid nanoparticles.

P2860

Q24308048-AB794FB6-4559-4BC7-8A9C-889D424C1BC2 Q26991739-36D041CD-73B3-46DD-95E9-EA5030B951BB Q26997989-71D35439-AD16-496E-959D-78882CFF7E3F Q28111991-4D0C001D-AA8F-43B5-8AAA-85F3A772347E Q30371220-1CAFBF3C-4070-4BAF-AF18-67C19A39C32A Q30419954-0F4FD8F7-7953-4C69-9D45-15CDDDAF3D64 Q30432964-DE5BE767-836A-4E46-8B86-8E3C537DD28D Q30435816-8C350EB9-6A63-42BA-89DC-C4354C929BD8 Q30474232-3F140CD4-35E5-4232-BF55-CEF528E4F1A2 Q30474756-B0FC5FE0-49E1-4A94-BE96-FBE89D52E981 Q33847097-2D6C93A5-C47B-49F9-85C6-2E691CD23A52 Q33860286-C88E147C-640A-4857-B256-A0C5BDA420CA Q34285100-CEDCF590-4535-4993-99C8-B4AC2B3C4EF1 Q34527874-4CD5139E-D104-45B3-A927-A95889171553 Q34632744-1A24FBE8-CC01-410C-83C8-082C8BB1DF32 Q35375156-C6AD9D5E-A15B-4774-95BF-19A80C300CE7 Q35892525-2EB44899-02D7-4D6A-A4D6-299F3D6FA813 Q35906830-E1048328-5855-4E59-A61C-660850203602 Q35956317-4FB4CDC3-A0F0-4F91-B0A5-6B23F346335F Q35978068-1C8F4418-70F5-43CD-94D9-0D30187057A4 Q36287728-5BE4700D-6722-4352-A3F6-1B19A5DE99CB Q36350809-621E325B-016A-4D7A-8AA5-24742A0CF5B0 Q36470824-00926138-E326-4F75-B8F9-CB8C4F0506A7 Q36554599-EC8B1D1D-C85C-4540-B1B8-189D349B3B0D Q36565615-CEC3A60A-1DEA-45BF-9D97-0B41E3C1FBF8 Q36728154-E8DC262B-C8F4-4FC1-843D-C0263B6EA050 Q36836438-893EB12F-F74B-4587-80A7-4CBC99C24598 Q36900018-C321143C-C844-400B-9069-09E2EC682734 Q36916404-4502EBC3-782A-4FAB-A278-1835D665FD44 Q36924403-5AB59C83-F584-4952-AAE8-C9EFA4EEF70C Q37291954-6B905C08-3D61-45EE-8DF9-C9C548266370 Q37483722-9913C9EC-35A9-4B48-AE8A-0F2D6174682E Q37772519-565D1642-9868-4437-81B8-23B1D19B47A6 Q37946259-E1EDD08B-9098-4727-AE3C-3B935789B7D8 Q38197608-E147509B-D5C8-40EE-B0BE-E707D8746F87 Q38225032-B9A9A8A1-2B90-4736-8436-CF2BD0514E44 Q38373652-60E7A71C-2795-439E-A651-F2370119ACD6 Q38747115-381DE4BF-7949-4396-8115-05A394780C89 Q39059946-F9860C42-3493-4354-9F36-548FE48B8659 Q39170861-267C06BE-0887-4FFE-8BA6-2621731B6762

P2860

Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse.

http://www.wikidata.org/entity/Q33835737

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effect of the selective kappa- ...... , and withdrawal in the mouse.

@ast

Effect of the selective kappa- ...... , and withdrawal in the mouse.

@en

type

label

Effect of the selective kappa- ...... , and withdrawal in the mouse.

@ast

Effect of the selective kappa- ...... , and withdrawal in the mouse.

@en

prefLabel

Effect of the selective kappa- ...... , and withdrawal in the mouse.

@ast

Effect of the selective kappa- ...... , and withdrawal in the mouse.

@en

P1433

Q33835737-52FE8DCA-2518-4B64-84FD-896E61D3EE55

P1476

Q33835737-9519C7B6-AAFA-4538-B652-F42D317CE83B

P2093

Q33835737-136F89E3-03F6-4516-AA34-5E9D462DD7B9

Q33835737-C9B79278-358F-472A-AAA4-FC99415A09B2

Q33835737-D5777B72-8B5D-439D-8514-8FA29329054D

Q33835737-E8D391AF-BCA0-4E42-BF3C-EF5C79113513

P2860

Q33835737-02317AFC-7BE5-4CC2-9CE7-DF2ED310C0A2

Q33835737-0C4918C0-70AD-4071-8EF1-342D35890C1A

Q33835737-0CB31D1F-3A97-43E4-AD64-E7390B8BAC57

Q33835737-15B90F85-627C-41C9-BA1B-52B4CB9C0E7C

Q33835737-269CD0DC-4022-4034-AF0D-BB50D610A4F5

Q33835737-3776E67E-12C0-46E6-AA34-D8D885920D50

Q33835737-44B2679D-B9D9-4D63-9B9D-67884029B583

Q33835737-4815A31C-6C3B-4A4F-BF5E-E9AEA35459CB

Q33835737-5A1A52FA-2EAC-49EE-83FD-C3D91997A9A0

Q33835737-65087F26-199D-4055-B68F-B67775934BBD

P2888

Q33835737-355DF3BB-A915-480D-BC80-99B337368748

P304

Q33835737-A06F8E79-5EED-43BD-A0EC-EBC2D721B670

P31

Q33835737-80288FDA-E781-421A-8036-8A5FEE5A4066

P356

Q33835737-B816F5AF-40AB-4698-BE5E-5CF03651B6C1

P433

Q33835737-BBB3E470-DD12-46AC-BB38-E6549DA14152

P478

Q33835737-856E2D23-84CF-4694-BE12-36D40459F027

P577

Q33835737-851AB819-DC88-4440-9F44-53017C793213

P5875

Q33835737-40E42D93-2ABB-4D44-8FAC-A56586F5FF59

P6179

Q33835737-1CE50255-66D9-46CA-8FAC-FCD620F07F25

P698

Q33835737-F3C7B919-E2E6-48C1-8113-8C3E9DDBBEFF

P932

Q33835737-EA4B6B51-37F8-45E3-BB16-2B3177886C79

P356

S00213-010-1803-1

P1433

Psychopharmacology

P1476

Effect of the selective kappa- ...... , and withdrawal in the mouse.

@en

P2093

Frank Ivy Carroll

http://www.w3.org/2001/XMLSchema#string

K J Jackson

http://www.w3.org/2001/XMLSchema#string

M I Damaj

http://www.w3.org/2001/XMLSchema#string

S S Negus

http://www.w3.org/2001/XMLSchema#string

P2860

Why people smoke

The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system

Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats

Psychotomimesis mediated by kappa opiate receptors

Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications

Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.

Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.

Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects.

Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats.

P2888

s00213-010-1803-1

P304

285-294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00213-010-1803-1

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

210

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41969681

http://www.w3.org/2001/XMLSchema#string

P6179

1042022732

http://www.w3.org/2001/XMLSchema#string

P698

20232057

http://www.w3.org/2001/XMLSchema#string

P932

2866121

http://www.w3.org/2001/XMLSchema#string